AbbVie Drops $10.9 Billion on Apogee in Its Biggest Bet Since 2019

AbbVie just opened its wallet wider than it has in years. On Monday the pharma giant announced it will buy Apogee Therapeutics for roughly $10.9 billion in cash, paying $135.11 a share — about a 60% premium to where Apogee closed before the long Juneteenth weekend. Apogee stock rocketed nearly 50% in premarket trading, and the deal instantly became the biggest thing AbbVie has done since its blockbuster Allergan takeover in 2019.

What AbbVie Is Actually Buying

This is not a revenue grab — it is a pipeline grab. Apogee has no approved drugs yet. What it does have is a stable of clinical-stage antibodies aimed at inflammatory and immune diseases, the exact turf where AbbVie already prints money. The crown jewel is zumilokibart, a long-acting antibody targeting IL-13 for atopic dermatitis, the chronic, itchy skin condition that has become one of the hottest battlegrounds in drug development.

The Humira Problem It Solves

AbbVie has spent years bracing for life after Humira, the immunology titan that once generated more than $20 billion a year before losing patent protection. Skyrizi and Rinvoq have picked up much of the slack, but Wall Street keeps asking the same question: what comes next? Buying Apogee is AbbVie's answer — a way to stretch its dominance in immunology into the next decade rather than defend a shrinking moat.

Why the 60% Premium

Sixty percent sounds rich, and it is. But premiums like this are the price of certainty in biotech. Late-stage immunology assets are scarce, and rivals like Sanofi, Eli Lilly, and Pfizer are all hunting the same targets. By paying up now, AbbVie locks out competitors and removes the risk that Apogee's data turns it into a bidding war later. For a company with deep pockets and an urgent need to refill the pipeline, overpaying today can be cheaper than missing out tomorrow.

What It Means for the M&A Backdrop

The Apogee deal did not land in a vacuum. It arrived the same morning CRH agreed to buy Arcosa, adding to a building wave of dealmaking as companies put balance sheets to work. After months of geopolitical jitters around Iran and oil, a fresh burst of large-cap M&A is a quiet signal that corporate boards are feeling steadier about the road ahead — even with markets opening cautiously.

The Catch for Investors

The deal still needs Apogee shareholder approval and regulatory sign-off, and management expects it to close in the third quarter. That means the easy money — that 60% pop — is largely gone for anyone not already holding the stock. For AbbVie shareholders, the real test comes later: whether zumilokibart and its sister antibodies actually deliver in the clinic, and whether $10.9 billion turns into the next Skyrizi or an expensive lesson in how hard late-stage drug development really is.

This article is for informational and educational purposes only and does not constitute investment advice. Always do your own research or consult a licensed financial professional before making investment decisions.